Study Looking at Response to the Nimenrix Vaccine in Healthy Infants
Study Looking at Response to the Nimenrix Vaccine in Healthy Infants. A Phase 3b, Open-Label, Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age.
Category & Conditions: Vaccine-related Conditions
Medicine: Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine)
ClinicalTrials.gov Identifier (NCT): NCT04819113
Protocol ID: C0921062
Open Plain Language Summary Result:
Click here